Pan African Clinical Trials Registry
South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202104807460491 Date of Approval: 14/04/2021
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title BFTAF Elderly Switch Study
Official scientific title Switching virally suppressed HIV-1 infected elderly adults (age ≥ 60 years) without prior confirmed virological failure from current anti-retroviral regimen to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF)
Brief summary describing the background and objectives of the trial Study Background: Current Kenya National ARV Guidelines and WHO Guidelines recommend first line therapy of TDF/3TC/DTG for adult PLHIV. This regimen has limitations, particularly for the aging PLHIV who are more likely to have pre-existing comorbidities and higher risk of developing comorbidities, including osteopenia, osteoporosis, and renal insufficiency. Abacavir, the preferred alternative NRTI in Kenya, is associated with increased cardiovascular risk that also limits its use in elderly populations. B/F/TAF is highly efficacious, well tolerated, co-formulated in a small pill, and does not have the same bone, renal or cardiovascular risks associated with currently recommended regimens in Kenya. We are not aware of any clinical trial to date that has been fully powered to compare ARV regimens for the increasing population of elderly PLHIV. Broad Objective: We will compare the efficacy, safety, and impact on bone mineral density of switching to B/F/TAF to that of remaining on current ARV regimen in a population of elderly patients (60 years old or greater) with no prior confirmed treatment failure in Kenya.
Type of trial RCT
Acronym (If the trial has an acronym then please provide)
Disease(s) or condition(s) being studied Infections and Infestations
Sub-Disease(s) or condition(s) being studied HIV/AIDS
Purpose of the trial Treatment: Drugs
Anticipated trial start date 07/06/2021
Actual trial start date 01/02/2022
Anticipated date of last follow up 02/01/2024
Actual Last follow-up date 18/03/2024
Anticipated target sample size (number of participants) 516
Actual target sample size (number of participants) 520
Recruitment status Completed
Publication URL
Secondary Ids Issuing authority/Trial register
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Randomised Simple randomization using a randomization table created by a computer software program Allocation was determined by the holder of the sequence who is situated off site Open-label(Masking Not Used)
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group Switch to BFTAF B/F/TAF will be administered as a single tablet fixed-dose combination of BIC/FTC/TAF (50mg/200mg/25mg) once daily 96 weeks On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to switch to B/F/TAF will be provided with a once-daily tablet that is a combination of bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF - 50mg/200mg/25mg) and followed up for 96 weeks 260
Control Group Continue with current ARV Regimen This will depend on the regimen the subject is using, for example: - if on TDF/3TC/EFV will receive one tablet once a day - if on TDF/3TC/DTG will receive one tablet once a day - if on AZT/3TC+DTG will receive one tablet of AZT/3TC twice a day and a tablet of DTG once a day 96 weeks On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to continue with their current ARV regimen will receive the first-line ARVs they were on at the time of enrollment for the 96-week follow-up period. 260 Active-Treatment of Control Group
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
1. Able and willing to understand and comply with the protocol requirements, instructions and restrictions 2. Able and willing to give informed consent 3. Age 60 years or above 4. Documented HIV-1 infection as confirmed by HIV-antibody testing as per the Kenya National Guidelines 5. Has been receiving an ARV regimen for at least 24 weeks 6. Documented HIV-1 RNA viral load < 50 copies/ml at least 12 weeks prior to enrollment and no viral rebound between the first viral load < 50 copies/ml and the screening viral load 7. HIV-1 RNA viral load < 50 copies/ml at screening (within 28 days prior to enrollment) 1. Confirmed treatment failure as defined by two consecutive HIV-1 RNA viral loads ≥ 50 copies/ml separated by at least 2 weeks, after at least 6 months on ART or after a documented HIV-1 RNA viral load < 50 copies/ml 2. Documented HIV-2 infection 3. Using any concomitant therapy disallowed as per the reference safety information and product labeling for the study drugs 4. Has AST and/or ALT at least 5-times greater than the upper limit of normal 5. Has a CrCl below 50 ml/min (as estimated using the Cockcroft-Gault estimate for glomerular filtration rate) 6. Documented opportunistic infection within 4 weeks prior to the study enrolment 7. Investigator opinion that the patient should switch or discontinue any ARV in their current regimen immediately for clinical reasons (e.g. anemia with Hb < 9.5 g/dl while currently on AZT; HBsAg positive without currently being on TDF or TAF plus 3TC or FTC; experiencing adverse events associated with any ARV in current regimen deemed significant enough to warrant immediate change in regimen) 8. Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator’s opinion, interfere with assessments or completion of the study 9. History or presence of allergy to the study drugs or their components 10. BMD monitoring population will also exclude any subject with a pre-existing condition which is likely to decrease validity of bone mineral density estimations (including pre-existing vertebral or bilateral hip fractures, lytic or blastic metastases, bilateral hip arthroplasty, or lumbar spine internal fixation) 80 and over: 80+ Year,Aged: 65+ Year(s),Middle Aged: 45 Year(s)-64 Year(s) 60 Year(s) 100 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 12/03/2021 KNH UoN Ethics and Research Committee
Ethics Committee Address
Street address City Postal code Country
Hospital Road, Upperhill Nairobi 00202 Kenya
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 08/01/2021 JOOTRH IERC
Ethics Committee Address
Street address City Postal code Country
Kisumu-Kakamega Highway Kisumu 40100 Kenya
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome To evaluate the non-inferiority of switching to B/F/TAF, compared to maintaining the current ARV regimen, in virologically suppressed HIV-1 positive elderly adults (≥ 60 years) with no prior confirmed virological failure, as determined by HIV-1 RNA PCR ≥ 50 copies/ml at week 48 Weeks 48
Primary Outcome To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine bone mineral density (BMD) after 48 weeks as measured by dual-energy x-ray absorptiometry (DXA) Weeks 48
Secondary Outcome To assess the impact of switching to B/F/TAF on development of virological failure at week 24 and 96 Week 24 and 96
Secondary Outcome To assess the impact of switching to B/F/TAF on maintenance of virological suppression at weeks 24, 48 and 96 Weeks 24, 48 and 96
Secondary Outcome To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine BMD at week 24 and 96 Week 24 and 96
Secondary Outcome To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in total hip BMD at weeks 24, 48 and 96 Week 24, 48 and 96
Secondary Outcome To evaluate the impact of switching to B/F/TAF on Fracture Risk Assessment Tool (FRAX) score at weeks 24, 48 and 96 Weeks 24, 48 and 96
Secondary Outcome To evaluate the impact of switching to B/F/TAF on patient satisfaction as measured by the HIV Treatment Satisfaction Questionnaire (HIVTSQ) at weeks 24, 48 and 96 Weeks 24, 48 and 96
Secondary Outcome To assess the impact of switching to B/F/TAF on change in CD4 count at weeks 24, 48 and 96 Weeks 24, 48 and 96
Secondary Outcome To assess the impact of switching to B/F/TAF on renal function at weeks 24, 48 and 96 Weeks 24, 48 and 96
Secondary Outcome To assess the impact of switching to B/F/TAF on change in total cholesterol at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To assess the impact of switching to B/F/TAF on change in low-density lipoprotein at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To assess the impact of switching to B/F/TAF on change in triglycerides at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To assess the impact of switching to B/F/TAF on change in total cholesterol to HDL ratio at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To assess the impact of switching to B/F/TAF on change in fasting blood glucose at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To evaluate the impact of switching to B/F/TAF on safety and tolerability (laboratory and clinical adverse events) at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To investigate the impact of switching to B/F/TAF on change in weight at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To investigate the impact of switching to B/F/TAF on change in body-mass index at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To investigate the impact of switching to B/F/TAF on change in waist-hip ratio at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To investigate the impact of switching to B/F/TAF on change in waist circumference at weeks 24 and 48 Weeks 24 and 48
Secondary Outcome To describe the genotypic resistance patterns for subjects meeting protocol-defined virological failure and HIV-1 RNA PCR ≥ 500 copies/ml at weeks 24 and 48 Weeks 24 and 48
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Kenyatta National Hospital Hospital Road, Upperhill Nairobi 00200 Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital Kisumu-Kakamega Highway, Kibuye Kisumu 40100 Kenya
FUNDING SOURCES
Name of source Street address City Postal code Country
Gilead Sciences Europe Limited 2 Roundwood Avenue, Stockley Park Uxbridge UB11 1AZ United Kingdom
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor University of Nairobi University Way Nairobi 00100 Kenya University
COLLABORATORS
Name Street address City Postal code Country
Loice Achieng College of Health Sciences, University of Nairobi Nairobi 00202 Kenya
Jeremy Penner College of Health Sciences, University of Nairobi Nairobi 00202 Kenya
Jared Mecha College of Health Sciences, University of Nairobi Nairobi 00202 Kenya
Anton Pozniak Chelsea and Westminster Hospital NHS Foundation London United Kingdom
Sanjay Bhagani Royal Free London NHS Foundation Trust London United Kingdom
Susan Njogo National AIDS and STIs Control Program, Kenya Nairobi Kenya
Simon Wahome Kenyatta National Hospital Nairobi Kenya
Sheila Eshiwani Kenyatta National Hospital Nairobi Kenya
Ruth Wanjohi Nairobi Hospital Nairobi Kenya
Florentius Ndinya Jaramogi Oginga Odinga Teaching and Referral Hospital Kisumu Kenya
Rukia Aksam Jaramogi Oginga Odinga Teaching and Referral Hospital Kisumu Kenya
Joseph Nkuranga College of Health Sciences, University of Nairobi Nairobi Kenya
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Loice Achieng loisea@uonibi.ac.ke +254722576984 University of Nairobi, Department of Clinical Medicine and Therapeutics
City Postal code Country Position/Affiliation
Nairobi 00202 Kenya BFTAF Principal Investigator
Role Name Email Phone Street address
Public Enquiries Joseph Nkuranga joseph.nku@gmail.com +254737223988 University of Nairobi, Department of Clinical Medicine and Therapeutics
City Postal code Country Position/Affiliation
Nairobi 00202 Kenya Trial Coordinator
Role Name Email Phone Street address
Scientific Enquiries Jeremy Penner pennerjak@gmail.com +254732391001 University of Nairobi, Department of Clinical Medicine and Therapeutics
City Postal code Country Position/Affiliation
Nairobi 00202 Kenya BFTAF Co Principal Investigator
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes Subject data used to generate the final manuscript from the study. The data will be de-identified and a data dictionary provided alongside the raw data. Study Protocol Immediately after publication of the final manuscript and for 24 months thereafter Access to IPD will be subject to the University of Nairobi data sharing requirements. Written requests should be submitted to the Principal Investigator providing a brief description of the individual or group making the request and detailing the reason for the same. Prior to sharing of the data, the requestor will be required to sign a data access and sharing agreement.
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Actual trial start date 13/07/2022 Regulatory approval of the trial and shipping of the investigational product took longer than anticipated 01 Feb 2022
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Anticipated date of last follow up 13/07/2022 Delayed start of the trial 06 Jan 2023 01 Aug 2023
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Anticipated date of last follow up 11/08/2023 Study follow-up period was extended to 96 weeks 01 Aug 2023 02 Jan 2024
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Completion date 25/10/2024 Updated 18 Mar 2024
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Final no of participants 13/07/2022 Protocol allowed enrolment upto 520 participants so as to ensure each arm had 258 participants 520
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Recruitment status 13/07/2022 Recruitment completed Not yet recruiting Closed to recruitment,follow-up continuing
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Recruitment status 13/06/2024 Completed 96 weeks of follow-up Closed to recruitment,follow-up continuing Completed
Section Name Field Name Date Reason Old Value Updated Value
Intervention Intervention List 11/08/2023 Study follow-up period extended to 96 weeks Experimental Group, Switch to BFTAF, B/F/TAF will be administered as a single tablet fixed-dose combination of BIC/FTC/TAF (50mg/200mg/25mg) once daily, 96 weeks, On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to switch to B/F/TAF will be provided with a once-daily tablet that is a combination of bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF - 50mg/200mg/25mg) and followed up for 96 weeks , 260,
Section Name Field Name Date Reason Old Value Updated Value
Intervention Intervention List 11/08/2023 Study follow-up period extended to 96 weeks Experimental Group, Switch to BFTAF, B/F/TAF will be administered as a single tablet fixed-dose combination of BIC/FTC/TAF (50mg/200mg/25mg) once daily, 48 weeks, On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to switch to B/F/TAF will be provided with a once-daily tablet that is a combination of bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF - 50mg/200mg/25mg) and followed up for 48 weeks , 258, Experimental Group, Switch to BFTAF, B/F/TAF will be administered as a single tablet fixed-dose combination of BIC/FTC/TAF (50mg/200mg/25mg) once daily, 96 weeks, On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to switch to B/F/TAF will be provided with a once-daily tablet that is a combination of bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF - 50mg/200mg/25mg) and followed up for 48 weeks , 260,
Section Name Field Name Date Reason Old Value Updated Value
Intervention Intervention List 11/08/2023 Study follow-up period extended to 96 weeks Control Group, Continue with current ARV Regimen, This will depend on the regimen the subject is using, for example: - if on TDF/3TC/EFV will receive one tablet once a day - if on TDF/3TC/DTG will receive one tablet once a day - if on AZT/3TC+DTG will receive one tablet of AZT/3TC twice a day and a tablet of DTG once a day , 48 weeks, On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to continue with their current ARV regimen will receive the first-line ARVs they were on at the time of enrollment for the 48-week follow-up period., 258, Active-Treatment of Control Group Control Group, Continue with current ARV Regimen, This will depend on the regimen the subject is using, for example: - if on TDF/3TC/EFV will receive one tablet once a day - if on TDF/3TC/DTG will receive one tablet once a day - if on AZT/3TC+DTG will receive one tablet of AZT/3TC twice a day and a tablet of DTG once a day , 96 weeks, On the day of enrollment, subjects will be randomized to continue their pre-enrollment ARV regimen or switch to B/F/TAF. Those who are randomized to continue with their current ARV regimen will receive the first-line ARVs they were on at the time of enrollment for the 96-week follow-up period., 260, Active-Treatment of Control Group
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 The primary outcome will only be assessed at week 48 Primary Outcome, To evaluate the non-inferiority of switching to B/F/TAF, compared to maintaining the current ARV regimen, in virologically suppressed HIV-1 positive elderly adults (≥ 60 years) with no prior confirmed virological failure, as determined by HIV-1 RNA PCR ≥ 50 copies/ml at week 48, Weeks 24 and 48 Primary Outcome, To evaluate the non-inferiority of switching to B/F/TAF, compared to maintaining the current ARV regimen, in virologically suppressed HIV-1 positive elderly adults (≥ 60 years) with no prior confirmed virological failure, as determined by HIV-1 RNA PCR ≥ 50 copies/ml at week 48, Weeks 48
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 The primary outcome will only be assessed at week 48 Primary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine bone mineral density (BMD) after 48 weeks as measured by dual-energy x-ray absorptiometry (DXA), Weeks 24 and 48 Primary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine bone mineral density (BMD) after 48 weeks as measured by dual-energy x-ray absorptiometry (DXA), Weeks 48
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To assess the impact of switching to B/F/TAF on development of virological failure at week 24, Week 24 Secondary Outcome, To assess the impact of switching to B/F/TAF on development of virological failure at week 24 and 96, Week 24 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To assess the impact of switching to B/F/TAF on maintenance of virological suppression at weeks 24 and 48, Weeks 24 and 48 Secondary Outcome, To assess the impact of switching to B/F/TAF on maintenance of virological suppression at weeks 24, 48 and 96, Weeks 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine BMD at week 24, Week 24 Secondary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in lumbar spine BMD at week 24 and 96, Week 24 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in total hip BMD at weeks 24 and 48, Week 24 and 48 Secondary Outcome, To evaluate the effect of B/F/TAF relative to maintaining the current ARV regimen on percentage change in total hip BMD at weeks 24, 48 and 96, Week 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To evaluate the impact of switching to B/F/TAF on Fracture Risk Assessment Tool (FRAX) score at weeks 24 and 48, Weeks 24 and 48 Secondary Outcome, To evaluate the impact of switching to B/F/TAF on Fracture Risk Assessment Tool (FRAX) score at weeks 24, 48 and 96, Weeks 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To evaluate the impact of switching to B/F/TAF on patient satisfaction as measured by the HIV Treatment Satisfaction Questionnaire (HIVTSQ) at weeks 24 and 48, Weeks 24 and 48 Secondary Outcome, To evaluate the impact of switching to B/F/TAF on patient satisfaction as measured by the HIV Treatment Satisfaction Questionnaire (HIVTSQ) at weeks 24, 48 and 96, Weeks 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To assess the impact of switching to B/F/TAF on change in CD4 count at weeks 24 and 48, Weeks 24 and 48 Secondary Outcome, To assess the impact of switching to B/F/TAF on change in CD4 count at weeks 24, 48 and 96, Weeks 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 14/08/2023 Study extended to 96 weeks Secondary Outcome, To assess the impact of switching to B/F/TAF on renal function at weeks 24 and 48, Weeks 24 and 48 Secondary Outcome, To assess the impact of switching to B/F/TAF on renal function at weeks 24, 48 and 96, Weeks 24, 48 and 96
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to the review comments Loice Achieng, College of Health Sciences, University of Nairobi, Nairobi, 00202, Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Jeremy Penner, College of Health Sciences, University of Nairobi, Nairobi, 00202, Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Jared Mecha, College of Health Sciences, University of Nairobi, Nairobi, 00202, Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Anton Pozniak, Chelsea and Westminster Hospital NHS Foundation, London, , United Kingdom
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Sanjay Bhagani, Royal Free London NHS Foundation Trust , London, , United Kingdom
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Susan Njogo, National AIDS and STIs Control Program, Kenya, Nairobi, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Simon Wahome, Kenyatta National Hospital, Nairobi, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Sheila Eshiwani, Kenyatta National Hospital, Nairobi, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Ruth Wanjohi, Nairobi Hospital, Nairobi, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Florentius Ndinya, Jaramogi Oginga Odinga Teaching and Referral Hospital , Kisumu, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Rukia Aksam, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, , Kenya
Section Name Field Name Date Reason Old Value Updated Value
Collaborators Collaborators List 14/04/2021 Response to review comments Joseph Nkuranga, College of Health Sciences, University of Nairobi, Nairobi, , Kenya